According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
A number of other equities analysts also recently issued reports on SELB. Mizuho set a $88.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a report on Friday, May 10th. Canaccord Genuity set a $40.00 price objective on shares of Mallinckrodt and gave the stock a buy rating in a report on Monday, March 18th. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $7.00 price objective on shares of Selecta Biosciences in a report on Friday, March 15th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $8.04.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.06. The firm had revenue of $0.01 million for the quarter. Equities analysts forecast that Selecta Biosciences will post -1.35 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Selecta Biosciences by 87.6% in the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock worth $34,000 after buying an additional 5,911 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Selecta Biosciences by 50.3% in the 4th quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock worth $63,000 after buying an additional 7,965 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Selecta Biosciences by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after buying an additional 8,500 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Selecta Biosciences by 251.6% in the 4th quarter. Deutsche Bank AG now owns 127,121 shares of the company’s stock worth $337,000 after buying an additional 90,970 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Selecta Biosciences by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock worth $466,000 after buying an additional 26,568 shares during the last quarter. 47.07% of the stock is currently owned by hedge funds and other institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Story: What is a good rate of return for a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.